TrialBMC infectious diseases2026

Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial.

Yihong Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.